Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

Abstract

This report provides updated recommendations for managing the drug-drug interactions that occur when using antiretroviral therapy during TB treatment. Changes from previous versions of these guidelines include a summary of data from clinical trials regarding timing of antiretroviral therapy among TB patients; drug interaction data for new antiretroviral drugs; and changes in dosing guidelines for rifabutin when co-administered with protease inhibitors, for nevirapine when co-administered with rifampin, and for raltegravir when co-administered with rifampin, as well as more detailed recommendations regarding co-treatment of TB and HIV among children and pregnant women. The report also includes pharmacokinetic data and data about immunologic response and virologic suppression (where available) for antiretroviral drugs that are licensed and available in the United States when administered in combination with antituberculosis drugs.